Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis

医学 杜瓦卢马布 肿瘤科 内科学 无容量 化疗 不利影响 肺癌 围手术期 养生 科克伦图书馆 癌症 荟萃分析 外科 免疫疗法
作者
Ting Mei,Qinghua Zhou,Youling Gong
出处
期刊:Clinical Oncology [Elsevier]
标识
DOI:10.1016/j.clon.2023.12.006
摘要

Aims The aim of this network meta-analysis was to elucidate the efficacy and safety of various immune checkpoint inhibitors (ICIs) used in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Materials and methods Data from randomised controlled trials comparing perioperative ICI–chemotherapy and chemotherapy alone were acquired from the EMBASE, Web of Science, Cochrane Library databases, PubMed, and meeting abstracts from inception until August 2023. The endpoints for this analysis were pathological complete response, event-free survival and treatment-related adverse events of any grade or adverse events of grade 3 or higher. Results In total, six randomised controlled trials with 2538 NSCLC patients were selected for this network meta-analysis. Compared with other ICIs, toripalimab + chemotherapy demonstrated increased pathological complete response rates and prolonged event-free survival in NSCLC. In patients with negative/low PD-L1 expression or squamous cell pathology, toripalimab + chemotherapy was the most effective regimen. In contrast, nivolumab + chemotherapy was preferable for patients with high PD-L1 expression or non-squamous cell pathology. Among the analysed regimens, toripalimab + chemotherapy presented the highest risk of adverse events of any grade, whereas nivolumab + chemotherapy showed the highest risk of grade 3–4 adverse events. Conversely, durvalumab + chemotherapy exhibited the lowest risk of grade 3–4 adverse events. Conclusions Among the evaluated perioperative immunochemotherapy regimens, toripalimab + chemotherapy indicated a significantly increased survival benefit for most resectable NSCLC patients. However, for high PD-L1 expression and non-squamous NSCLC patients, nivolumab + chemotherapy provided the most potent outcomes. Perioperative durvalumab + chemotherapy is a relatively safe treatment. The findings of this investigation are expected to assist clinicians in making informed decisions among promising treatment options.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
healer完成签到,获得积分20
1秒前
刘梦发布了新的文献求助10
2秒前
2秒前
shilin完成签到,获得积分10
2秒前
咔叽麻完成签到,获得积分10
3秒前
简单的张哈哈完成签到,获得积分10
4秒前
4秒前
4秒前
楠沐发布了新的文献求助10
5秒前
田様应助拉长的黄豆采纳,获得10
6秒前
gjww应助cui采纳,获得10
6秒前
爱钓鱼的研究僧1115完成签到,获得积分10
6秒前
ding应助畅快自行车采纳,获得10
7秒前
听话的慕卉完成签到,获得积分10
7秒前
大模型应助懵懂的芫采纳,获得10
8秒前
传统的如霜完成签到,获得积分10
8秒前
田様应助普通人采纳,获得10
9秒前
顺心冬易完成签到 ,获得积分10
9秒前
ytli完成签到 ,获得积分10
10秒前
10秒前
Alva完成签到,获得积分10
10秒前
10秒前
ao20000106发布了新的文献求助10
11秒前
顺心的水云完成签到,获得积分10
13秒前
呆崽发布了新的文献求助10
15秒前
细心枫叶完成签到,获得积分10
16秒前
宋宋完成签到,获得积分10
16秒前
17秒前
17秒前
共享精神应助依古比古采纳,获得10
18秒前
花火完成签到,获得积分10
19秒前
jdjdjn完成签到,获得积分10
19秒前
00gi完成签到,获得积分10
20秒前
20秒前
20秒前
zombie完成签到,获得积分10
20秒前
20秒前
FionaYoung完成签到,获得积分10
20秒前
20秒前
21秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
薩提亞模式團體方案對青年情侶輔導效果之研究 400
3X3 Basketball: Everything You Need to Know 310
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2387852
求助须知:如何正确求助?哪些是违规求助? 2094340
关于积分的说明 5272530
捐赠科研通 1821070
什么是DOI,文献DOI怎么找? 908439
版权声明 559289
科研通“疑难数据库(出版商)”最低求助积分说明 485336